Milestone Pharmaceuticals is trading at $0.80, up 5.03%, with no specific company catalyst identified for October 12.
- The latest company announcement was October 9, when Milestone reported the first European participant enrolled in its Phase 3 ReVeRA-301 trial.
- Available coverage does not establish that announcement as the reason for the October 12 move.
- Supplied market context was mixed; no major index moved more than 0.5% in the same direction to explain the gain.